Biomarkers and antibodies

Through in-house research and partnership programs with pharmaceutical companies and academic groups, we are continuously expanding our extensive portfolio of state-of-the-art biomarkers and antibodies. These qualified antibodies are exclusively available to our partners and collaborators.

Robust and reliable assays for cerebrospinal fluid (CSF) and blood can be developed with these antibodies to detect neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury.

Discover our portfolio below. Request a test-sample to verify the unique performance of our materials or let us know how we can help you.

Get in touch

ADx monoclonal antibodies

Amyloid

Amyloid-beta is a useful biomarker for the detection of the Alzheimer pathology, even in an early stage. Decreased amyloid-beta 42/40 ratio in CSF and plasma correlates highly with the presence of amyloid plaques in Alzheimer brains.

Available antibodies

ADx101	Mouse monoclonal antibody against human β Amyloid 1-x	1 specific
ADx102	Mouse monoclonal antibody against human β Amyloid x-42	42 specific
ADx103	Mouse monoclonal antibody against human β Amyloid x-40	40 specific
ADx401	Mouse monoclonal antibody against human BACE-1
ADx402	Mouse monoclonal antibody against human BACE-1

Literature

Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.

Emma van den Berg, Iris Kersten, Gunnar Brinkmalm, Kjell Johansson, Anna M. de Kort, Catharina J. M. Klijn, Floris H. B. M. Schreuder, Johan Gobom, Erik Stoops, Erik Portelius, Eleni Gkanatsiou, Henrik Zetterberg, Kaj Blennow, Hinke B. Kuiperij, Marcel M. Verbeek. Journal of Neurochemistry 2024 Feb.

Decreased cerebrospinal fluid Aβ 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy

De Kort et al. Ann Neurol. Jun 2023 doi:10.1002/ana.26610

Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease

Thijssen et al. Sci Rep. 2021 May 6;11(1):9736.

Tau

Total tau and P-tau are good indicators of neuronal damage. P-tau specifically measures damage caused by Alzheimer’s disease. In contrast, total tau is a general marker, which can also be used to determine severe concussion.

Available anti Tau antibodies

ADx201	Mouse monoclonal antibody against human total tau	Proline rich domain
ADx202	Mouse monoclonal antibody against human total tau	Proline rich domain
ADx204	Mouse monoclonal antibody against human total tau	N-terminal tau
ADx215	Mouse monoclonal antibody against human total tau	N-terminal tau
ADx216	Mouse monoclonal antibody against human total tau	C-terminal tau
ADx217*	Mouse monoclonal antibody against human total tau	N-terminal
ADx218	Mouse monoclonal antibody against human total tau (Recombinant)	N-terminal tau

*CSF use only

Literature

Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET

Steffi De Meyer, Jolien M Schaeverbeke, Emma S Luckett, Mariska Reinartz, Elena R Blujdea, Isabelle Cleynen, Patrick Dupont, Koen Van Laere, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Guglielmo di Molfetta, Henrik Zetterberg, Nicholas J Ashton, Charlotte E Teunissen, Koen Poesen, Rik Vandenberghe.
Brain Communications 2024 May.

Prognostic value of a novel plasma pTau217 assay for amyloid accumulation in healthy elderly

Meyer, S.D., Luckett, E.S., Schaeverbeke, J., Laere, K.V., Vanbrabant, J., Vanmechelen, E., Dupont, P., Molfetta, G.D., Zetterberg, H., Ashton, N.J., Poesen, K. and Vandenberghe, R., Alzheimer’s Dement 2025 January

Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics

Rosseels et al, J Biol Chem 2015;290:4059.

ADx252	Rabbit monoclonal antibody against human P-tau181	Phosphorylated Threonine 181 specific
ADx253	Mouse monoclonal antibody against human P-tau231	Phosphorylated Threonine 231 specific
ADx254*	Mouse monoclonal antibody (Fab) fragment against human P-tau217	Phosphorylated Threonine 217 specific
RD-085	Mouse monoclonal antibody against human P-tau217	Phosphorylated Threonine 217 specific
ADx257	Mouse monoclonal antibody against human P-tau231 (Recombinant)	Phosphorylated Threonine 231 specific

*CSF use only

Literature

Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET

Prognostic value of a novel plasma pTau217 assay for amyloid accumulation in healthy elderly

Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

Synapses

Neurons are interconnected by multiple synapses. In Alzheimer’s disease, synapses show gradual degeneration. Neurogranin and Neuronal Pentraxin 2 (NPTX2) in CSF are good biomarkers for synapse integrity. They will help predict the progression of the disease.

Available antibodies

ADx403	Mouse monoclonal antibody against human neurogranin	N-terminal
ADx451	Mouse monoclonal antibody against human truncated neurogranin	Specific for C-terminal truncation at P75
ADx409	Mouse monoclonal antibody against human NPTX-2
ADx410	Mouse monoclonal antibody against human NPTX-2

Literature

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Shreyasee Das, Marie-Paule E. van Engelen, Julie Goossens, Dirk Jacobs, Bram Bongers, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Charlotte E. Teunissen, Eugeen Vanmechelen & Inge M. W. Verberk.

Alz Res Therapy 2024 Feb.

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum

Goossens et al. Alz Res Therapy 2023 Oct doi: doi.org/10.1186/s13195-023-01336-0

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study

Willemse et al, Clin Chem 2018;64:927.

Synuclein

The concentration of α-synuclein in CSF is linked to the presence of Lewy bodies in the brain, which are typically found in the brains of Parkinson’s disease patients. Other α-synuclein forms are in development.

Available antibodies

ADx301

Rabbit monoclonal antibody against human α-synuclein

Literature

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Alz Res Therapy 2024 Feb.

Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity

Lashuel et al. NPJ Parkinsons Dis. 2022 Oct;8(1):136.

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study

Mollenhauer et al, J Neurochem 2019;149:126.

Available antibodies

ADx206	Mouse monoclonal antibody against human Nf-L
ADx209	Mouse monoclonal antibody against human Nf-L
ADx601	Rabbit monoclonal antibody against human sTREM-2
ADx602	Rabbit monoclonal antibody against human sTREM-2

Commercial immunoassays

ADx markers were developed and commercialized in collaboration with our partners and are adaptable to any technology.

Please get in touch to request more information.

Get in touch

Biomarkers and antibodies

ADx monoclonal antibodies

Amyloid

Available antibodies

Literature

Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy.

Decreased cerebrospinal fluid Aβ 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy

Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease

Tau

Available anti Tau antibodies

Literature

Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET

Prognostic value of a novel plasma pTau217 assay for amyloid accumulation in healthy elderly

Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics

Available anti phosphorylated Tau antibodies

Literature

Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET

Prognostic value of a novel plasma pTau217 assay for amyloid accumulation in healthy elderly

Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

Synapses

Available antibodies

Literature

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum

Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study

Synuclein

Available antibodies

Literature

The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease

Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study

Other

Available antibodies

Commercial immunoassays

Our Company

Navigation

Information

Credits